Studies have shown that CD64 protein has tissue-targeting peptide and humanised monoclonal antibody, and the combination of CD64 protein-containing extracellular vesicles (dtEV) and low-dose chemotherapy drug gemcitabine can effectively inhibit the growth and metastasis of pancreatic ductal adenocarcinoma in mice, and prolong the survival rate of the animals [34]. The gene discussed is FCGR1A; the disease is pancreatic ductal adenocarcinoma.